ImmunoPrecise Antibodies Ltd (CVE:IPA) (OTCQB:IPATF) on Friday provided an update on its research activities for the coronavirus (COVID-19), outlining its workflow for experimental vaccines and therapeutics for the research community.
In a statement, the company said its multi-targeting approach combines various SARS-CoV-2 spike protein forms with its diverse technologies. The SARS-CoV-2 virus causes COVID19, which is the disease.
ImmunoPrecise said it anticipates that it can accelerate anti-SARS-CoV-2 human antibody discovery, targeting multiple viral epitopes and mechanisms of viral evasion, immunizing Ligand Pharmaceuticals’ (NASDAQ:LGND) OmniRat animals using the company's Rapid Prime protocol followed by its B cell Select and hybridoma generation in parallel with human, naive phage library screening.
Subsequent high-throughput binding assays, computational Artemis optimization, and protein interaction analyses permit faster preclinical lead selection, ImmunoPrecise said.
"In addition to using our antibody discovery platforms for the potentially rapid identification of a diverse panel of fully SARS-CoV-2-specific antibodies, we aim to target additional novel epitopes which are likely inaccessible to conventional antibody formats by screening our in-house, highly complex, VHH repertoire (collection of variable regions of heavy chain antibodies, a region which binds to the target immunogen)," said Ilse Roodink, chairwoman of Talem Therapeutics’ scientific advisory committee and Coronavirus global project leader. Talem is an ImmunoPrecise subsidiary.
"Due to the relative high sequence homology of VHHs with human antibodies, extensive humanization is not required and therefore, our discovery strategy mixture will significantly contribute to the fast generation of a monoclonal antibody cocktail with broad epitope coverage and diverse functionalities, which is key to successful development of an effective, long-lasting therapy with a high safety profile," Roodink added.
Apart from the various SARS-CoV-2 spike protein forms which have been produced for use in therapeutic development, data obtained during the discovery of lead antibody candidates may be of significant value in the reverse-engineering of vaccine candidates used to formulate an effective low-risk, vaccine, ImmunoPrecise said.
Contact the author: firstname.lastname@example.org
Follow him on Twitter @PatrickMGraham